Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Pioneering Biomedicine in the Greater Bay Area

Image Credits: CUHK, Press Release
Getting your Trinity Audio player ready...

The Faculty of Medicine at The Chinese University of Hong Kong (CUHK) (CU Medicine), has achieved a significant milestone by establishing an internationally accredited biobank. Known as CU-Med Biobank, this accomplishment positions CUHK as a driving force in advancing biomedicine within the Guangdong-Hong Kong-Macao Greater Bay Area. Furthermore, it solidifies Hong Kong’s emergence as a key biomedical research hub in the region.

The construction of the biobank began at the Prince of Wales Hospital in 2019, and after years of dedicated efforts, CU Medicine has received prestigious international accreditation [ISO 20387:2018(en)] from A2LA. This accreditation serves as a testament to the biobank’s adherence to high standards and places it among a select few in the Asia-Pacific region.

Alongside a biobank in South Korea, CU-Med Biobank is one of only two facilities that meet the stringent international requirements. This accreditation serves as a validation of Hong Kong’s potential to become a significant centre for new drug research and development within the Greater Bay Area.

Accelerating the R&D of new drugs

To drive advancements in new drug development and pioneering diagnostic technologies, it is essential to have both software and hardware capabilities, including the establishment of a biobank. A biobank serves as a crucial facility for the organised storage of clinical data and biological specimens. It goes beyond mere sample storage and encompasses robust management systems for handling diverse biological samples and conducting precise multi-omics analysis.

The Dean of Medicine and Head of the Steering Committee of CU-Med Biobank at CU Medicine highlighted the significance of biobanking standards. These standards not only impact the quality of academic research but also determine the potential for new drug development.

Achieving international accreditation for the biobank demonstrates CU Medicine’s ability to attract collaborations with top global scientific research teams and multinational pharmaceutical companies. This accreditation enhances CU Medicine’s credibility and positions it to collaborate with the Hospital Authority, contributing to the transformation of Hong Kong into a research and new drug development hub within the Guangdong-Hong Kong-Macao Greater Bay Area.

The Co-Head of the Executive Committee of CU-Med Biobank and is a Professor at the Department of Medicine and Therapeutics at CU Medicine, highlights the rapid development of genomic research in the past two decades, driven by the emergence of precision medicine and personalised medicine.

A biobank is regarded as a valuable asset as it not only stores vast amounts of genetic data but also biospecimens that have the potential to generate various other biomarker information. This potential makes biobanks crucial in advancing medical research.

CU Medicine has been committed to achieving international standards right from the initial preparation stage of establishing their biobank. Through five years of dedicated work in system establishment, operation, and preparation, coupled with an extensive review process spanning over four months, the team has successfully obtained the ISO 20387:2018(en) accreditation this year.

The Scientific Officer of CU-Med Biobank highlighted the meticulous adherence to regulations in four key areas: sample acquisition, processing, storage, and distribution. It is through this strict compliance that the biobank has earned its international accreditation. This recognition is expected to have a significant impact on the advancement of biomedical research.

The accreditation will play a crucial role in promoting large-scale international research collaborations. It will attract scientific research teams and pharmaceutical institutions from both local and international settings, including mainland China, to engage in collaborative efforts.

Ultimately, this will enhance the efficiency and elevate the level of biomedical research conducted within the biobank, further establishing CU Medicine as a prominent centre for cutting-edge technological advancements in the field.

CU Medicine has made notable advancements in biomedical research through its CU-Med Biobank. Research teams have used the biobank for large-scale genomic studies, including breast cancer research, leading to the establishment of a dedicated Breast Cancer Biobank.

The Hong Kong Diabetes Biobank has contributed to identifying genetic and biological markers associated with diabetes and its complications. Additionally, CU Medicine’s Microbiota I-Centre has established a significant mother-infant cohort, positioning Hong Kong as a prominent hub in the microbiota industry.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and consulting services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,800 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently, and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity, and service. For more information, visit